European Archives - Page 539 of 1163 - European Medical Journal

EMJ wins a Queen's Award for Enterprise

Our company, EMJ, is one of 225 organisations nationally to be recognised with a Queen’s Award for International Trade.

Percutaneous Nephrostomy Insertion Training: An Overview

Urinary tract obstruction is a common acute presentation to secondary care. Relief of upper urinary tract obstruction is usually performed in acute cases, or in chronic obstruction where treatment of the causative process is not immediately possible.

The Current Treatment Landscape in Head and Neck Cancer

This webinar will explore the current evidence and management of head and neck cancer especially focusing on older adults. The speaker…

Routine vaccinations: road to recovery

The pharmaceutical industry needs to help restoring pre-pandemic routine vaccination levels and protect populations worldwide.

2022 pharma predictions – where are we now?

In this episode, at the season’s half way point, Marc, Helena and Isabel look back at our 2022 predictions for pharma industry – were our guests right?

Silent Myocardial Infarction in Hypereosinophilic Syndrome Overlapped with JAK2-Mediated Essential Thrombocytosis

JAK2-mediated thrombosis overlapping with silent myocardial infarction and an elevated eosinophil count associated with neuropathy…

Zika Virus Infection and Pathogenesis

Zika virus is associated with central nervous system involvement and a congenital syndrome following Zika infection in pregnancy…

Spring 2022 Highlights

In this one-off special, we look back at some of the most memorable moments from the 2022 series of the EMG Health Podcast.

IVDR – the new European In-Vitro Diagnostics market regulations and its implications for the microbiology laboratories

We discuss the differences between the IVDD and IVDR regulations in Europe, the differences and similarities between different countries.

New antibiotics, its implementation and adoption and the role they play in assuring more effective health treatments

We discuss the process of developing new drugs, the barriers to adoption of new available medicines by healthcare providers and practitioners.